+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Retinal Disorder Treatment Market by Disease, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012391
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior leaders navigating the evolving landscape of retinal disorder treatment face significant opportunities and challenges as innovation reshapes both care delivery and market dynamics. The retinal disorder treatment market continues its upward trajectory, shaped by advances in gene therapy, digital health, and global demographic trends. This report offers a focused, actionable overview designed for decision-makers responsible for strategy, investment, and operational planning.

Market Snapshot: Retinal Disorder Treatment Market Overview

The retinal disorder treatment market grew from USD 9.38 billion in 2024 to USD 10.27 billion in 2025 and is projected to expand at a CAGR of 8.97%, reaching USD 15.72 billion by 2030. Market expansion is notably driven by increased disease prevalence, aging populations, and persistent innovation across drug classes, delivery methods, and digital diagnostics.

Scope & Segmentation: Defining the Therapeutic Landscape

  • Disease Categories: Age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion, each presenting distinct clinical and therapeutic needs.
  • Disease Subtypes: Dry and wet forms of age-related macular degeneration; nonproliferative and proliferative diabetic retinopathy stages; branch and central vein occlusion types.
  • Drug Classes: Anti-VEGF therapies (aflibercept, bevacizumab, brolucizumab, ranibizumab) and corticosteroids (dexamethasone implant, fluocinolone acetonide, triamcinolone acetonide).
  • Routes of Administration: Intravitreal injection, topical, subretinal, and oral therapies offer tailored options for diverse clinical scenarios.
  • End Users: Ambulatory surgical centers, multispecialty clinics, ophthalmology clinics, home healthcare programs, hospitals (inpatient and outpatient settings).
  • Distribution Channels: Hospital, online, and retail pharmacy networks supporting therapy access and logistical differentiation.
  • Regions Covered: Americas (key states and countries), Europe, Middle East & Africa, and Asia-Pacific, addressing mature and emerging markets with unique payer and infrastructure profiles.
  • Key Companies Profiled: Regeneron Pharmaceuticals, Novartis AG, F. Hoffmann-La Roche, Bayer AG, AbbVie, Santen Pharmaceutical, Bausch Health, Alimera Sciences, Carl Zeiss Meditec, NIDEK.

Key Takeaways for Decision-Makers

  • Advancements in gene therapies and digital diagnostic tools are redefining the standard of retinal care, offering new patient management models and therapeutic durability.
  • Innovation in sustained-release formulations and microdelivery devices seeks to lower treatment frequency and increase compliance, impacting operational planning and patient engagement.
  • Regional market adoption varies significantly, with reimbursement policies and regulatory frameworks shaping access to new therapies and influencing localization strategies.
  • Strategic partnerships and targeted acquisitions are central to pipeline development, technology integration, and portfolio expansion in a consolidating competitive landscape.
  • Data-driven platforms and real-world evidence generation support value-based pricing, aiding negotiations with payers and increasing acceptance of high-impact interventions.
  • A focus on patient-centric services and adaptable supply chains strengthens positioning amid fluctuating regulatory climates and global health events.

Tariff Impact on Ophthalmic Supply Chains

Recent US tariffs on pharmaceutical ingredients and medical device components have increased input costs and procurement challenges for manufacturers, especially those reliant on imported materials for intravitreal formulations. Larger companies are investing in regional manufacturing hubs to minimize exposure and safeguard supply continuity, while smaller firms explore domestic partnerships to remain competitive. These changes are driving a shift toward agile supply chain design, with providers renegotiating vendor agreements and optimizing inventory management to support uninterrupted care delivery. Payers are placing greater emphasis on value demonstration, accelerating moves toward outcome-driven contracting.

Methodology & Data Sources

This report leverages a mix of primary research—including expert interviews with retinal specialists, payers, and supply chain leaders—and comprehensive secondary research from peer-reviewed journals, regulatory documents, company filings, and proprietary market intelligence databases. Data triangulation and peer review ensure robust, credible insights into both trends and strategic imperatives.

Why This Report Matters

  • Enables senior executives to benchmark portfolio positioning and partnership strategies against changing market forces and evolving care models.
  • Delivers segment-specific insights to inform product development, regional expansion, and operational efficiency priorities in the retinal care domain.
  • Supports data-driven decisions on supply chain resilience, regulatory risk mitigation, and payer engagement, improving strategic outcomes.

Conclusion

The retinal disorder treatment market is moving rapidly toward more individualized, technology-enabled care. Organizations aligning innovation pipelines with dynamic market requirements will be best positioned to realize growth and sustain leadership in retinal health.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Retinal Disorder Treatment Market, by Disease
8.1. Introduction
8.2. Age-Related Macular Degeneration
8.2.1. Dry Age-Related Macular Degeneration
8.2.2. Wet Age-Related Macular Degeneration
8.3. Diabetic Retinopathy
8.3.1. Nonproliferative
8.3.2. Proliferative
8.4. Retinal Vein Occlusion
8.4.1. Branch Vein Occlusion
8.4.2. Central Vein Occlusion
9. Retinal Disorder Treatment Market, by Drug Class
9.1. Introduction
9.2. Anti-VEGF
9.2.1. Aflibercept
9.2.2. Bevacizumab
9.2.3. Brolucizumab
9.2.4. Ranibizumab
9.3. Corticosteroids
9.3.1. Dexamethasone Implant
9.3.2. Fluocinolone Acetonide
9.3.3. Triamcinolone Acetonide
10. Retinal Disorder Treatment Market, by Route Of Administration
10.1. Introduction
10.2. Intravitreal Injection
10.3. Oral
10.4. Subretinal
10.5. Topical
11. Retinal Disorder Treatment Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Clinics
11.3.1. Multispecialty Clinics
11.3.2. Ophthalmology Clinics
11.4. Home Healthcare
11.5. Hospitals
11.5.1. Inpatient
11.5.2. Outpatient
12. Retinal Disorder Treatment Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Americas Retinal Disorder Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Retinal Disorder Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Retinal Disorder Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Regeneron Pharmaceuticals, Inc.
16.3.2. Novartis AG
16.3.3. F. Hoffmann-La Roche Ltd
16.3.4. Bayer AG
16.3.5. AbbVie Inc.
16.3.6. Santen Pharmaceutical Co., Ltd.
16.3.7. Bausch Health Companies Inc.
16.3.8. Alimera Sciences, Inc.
16.3.9. Carl Zeiss Meditec AG
16.3.10. NIDEK Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. RETINAL DISORDER TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. RETINAL DISORDER TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. RETINAL DISORDER TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. RETINAL DISORDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. RETINAL DISORDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RETINAL DISORDER TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY NONPROLIFERATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PROLIFERATIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY BRANCH VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CENTRAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY FLUOCINOLONE ACETONIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SUBRETINAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MULTISPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 77. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 78. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 79. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 80. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 81. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 83. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 84. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 87. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 88. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 90. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 91. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 92. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 93. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 95. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 96. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 99. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 151. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 152. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 153. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 154. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 155. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 156. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 157. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 160. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 161. GERMANY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 163. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 164. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 165. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 166. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 168. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 169. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 172. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 173. FRANCE RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 187. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 188. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 189. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 190. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 191. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 192. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 193. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 196. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 197. ITALY RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 199. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 200. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 201. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 202. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 203. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 204. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 205. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 208. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 209. SPAIN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 247. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 248. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 249. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 250. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 251. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 252. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 253. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 256. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 257. DENMARK RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 269. NETHERLANDS RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 271. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 272. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 273. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 274. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 275. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 276. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 277. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 280. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 281. QATAR RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 283. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 284. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 285. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 286. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 287. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 288. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 289. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 290. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 292. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 293. FINLAND RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 304. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 305. SWEDEN RETINAL DISORDER TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. NIGERIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 307. NIGERIA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 308. NIGERIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 309. NIGERIA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 310. NIGERIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Retinal Disorder Treatment market report include:
  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • AbbVie Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Bausch Health Companies Inc.
  • Alimera Sciences, Inc.
  • Carl Zeiss Meditec AG
  • NIDEK Co., Ltd.

Table Information